DNA instability in replicating Huntington's disease lymphoblasts

Milena Cannella  
*IRCCS Neuromed, Italy*

Vittorio Maglione  
*IRCCS Neuromed, Italy*

Tiziana Martino  
*IRCCS Neuromed, Italy*

Giuseppe Ragona  
*University "Sapienza," Italy*

Luigi Frati  
*University "Sapienza," Italy*

See next page for additional authors

Follow this and additional works at: [https://uknowledge.uky.edu/toxicology_facpub](https://uknowledge.uky.edu/toxicology_facpub)

Part of the Medical Toxicology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
DNA instability in replicating Huntington's disease lymphoblasts

Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/1471-2350-10-11

Notes/Citation Information
Published in *BMC Medical Genetics*, v. 10, 11.

© 2009 Cannella et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors
Milena Cannella, Vittorio Maglione, Tiziana Martino, Giuseppe Ragona, Luigi Frati, Guo-Min Li, and Ferdinando Squitieri

This article is available at UKnowledge: https://uknowledge.uky.edu/toxicology_facpub/14
DNA instability in replicating Huntington's disease lymphoblasts
Milena Cannella¹, Vittorio Maglione¹, Tiziana Martino¹, Giuseppe Ragona², Luigi Frati², Guo-Min Li³ and Ferdinando Squitieri*¹

Address: ¹Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS), Italy, ²Department of Experimental Medicine, University "Sapienza", Rome, Italy and ³Department of Toxicology, University of Kentucky College of Medicine, Lexington (KY), USA

Email: Milena Cannella - genetics@neuromed.it; Vittorio Maglione - genetics@neuromed.it; Tiziana Martino - genetics@neuromed.it; Giuseppe Ragona - giuseppergagona@uniroma1.it; Luigi Frati - luigifrati@uniroma1.it; Guo-Min Li - gml@uky.edu; Ferdinando Squitieri* - neurogen@neuromed.it

* Corresponding author

Abstract

Background: The expanded CAG repeat in the Huntington's disease (HD) gene may display tissue-specific variability (e.g. triplet mosaicism) in repeat length, the longest mutations involving mitotic (germ and glial cells) and postmitotic (neurons) cells. What contributes to the triplet mutability underlying the development of HD nevertheless remains unknown. We investigated whether, besides the increased DNA instability documented in postmitotic neurons, possible environmental and genetic mechanisms, related to cell replication, may concur to determine CAG repeat mutability. To test this hypothesis we used, as a model, cultured HD patients' lymphoblasts with various CAG repeat lengths.

Results: Although most lymphoblastoid cell lines (88%) showed little or no repeat instability even after six or more months culture, in lymphoblasts with large expansion repeats beyond 60 CAG repeats the mutation size and triplet mosaicism always increased during replication, implying that the repeat mutability for highly expanded mutations may quantitatively depend on the triplet expansion size. None of the investigated genetic factors, potentially acting in cis to the mutation, significantly influence the repeat changes. Finally, in our experiments certain drugs controlled triplet expansion in two prone-to-expand HD cell lines carrying large CAG mutations.

Conclusion: Our data support quantitative evidence that the inherited CAG length of expanded alleles has a major influence on somatic repeat variation. The longest triplet expansions show wide somatic variations and may offer a mechanistic model to study triplet drug-controlled instability and genetic factors influencing it.

Background

The Huntington's disease (HD) mutation influences age at onset through its CAG repeat length, a genetic feature that is unstable during intergenerational parent-child transmission [1]. Transmitting males generally cause the highest expansions in successive generations. Expansion size progressively increases through a so-called multi-step mechanism [2,3], thus providing the molecular explanation for onset anticipation. Large CAG expansions above 60 repeats cause a severe phenotype leading to juvenile HD (JHD) [4]. The higher the expanded repeat length, the more instable is the triplet stretch in somatic and germinal
tissues [5-10]. In the brain of patients with another CAG expansion mutation disease, dentato-rubral pallido-luysian atrophy (DRPLA), dividing glial cells carry the largest CAG mutations [11,12], whereas, in HD, differentiating nonreplicating neurons carry the largest expansion mutations [13,14]. In other non-CAG triplet diseases with an excess of repeat expansions involving thousands of trinucleotides, somatic time-dependent variation in a CTG or GAA polymorphic stretch in the mutated alleles has also been documented in lymphoblasts, indicating lymphoblastoid cells as a valuable source for longitudinal analyses of triplet instability, mosaicism variability and genetic transmission [15,16].

Our purpose in this study was to investigate whether, besides the mechanisms influencing the CAG repeat mutability in HD terminally differentiated and nondividing neurons [13,14], cell division may contribute to DNA instability. To do so, we sought possible length- and time-dependent variability in the HD gene in serially passaged lymphoblastoid cell lines established from patients, after their passages in culture over time. We also studied the possible dependence of the somatic triplet variation and mosaicism (heterogeneity of the repeat length in the tissue) on CAG mutation length, on factors acting in cis or in trans to the mutation, and on drug-induced contraction of the mutation size.

Methods

Passaged cell lines and DNA study

Peripheral blood samples were collected after written informed consent. The subjects' consent was obtained according to the Declaration of Helsinki (Br Med J 1991; 302: 1194) after approval of the Bioethical Committee of Neuromed Institute. We obtained three blood samples from each subject; lymphocytes were isolated by differential centrifugation through Ficoll (Cederlane Laboratories) and transformed by Epstein Barr virus separately and in parallel from each sample as described [17] and according to the standard protocol [18]. A total 58 HD lymphoblastoid cell lines from subjects with a wide range of CAG expanded repeats, including low (39–41 CAG) and highly penetrant (60 CAG and more) mutations conventionally considered causing juvenile HD (Table 1), were serially passaged for at least 6 months (range: 6–12 months) to analyse longitudinal repeat variation during the passage time as previously described [17]. Groups of about 10 cell lines were cultured in parallel. All groups shared one identical clone obtained from one cell line as a marker of CAG size variability. This strategy was used to exclude potential length variability in the same cell cultures, and to highlight a potential influence on mutation size and mosaicism of yet unknown environmental factors during culture (for details see Additional file 1).

Table 1: Demographic characteristics of the patients and genetic characteristics of the lymphoblastoid cell lines in the patients with Huntington’s disease.

| Cell lines                        | No. | Gender Male/Female | Mean expanded CAG ± SD (range) | Mean Age at onset ± SD (range) | Mean Over-time Triplet variation ± SD (ΔCAG) | Mean Mosaicism degree ± SD (No. peaks) | Expansions/contractions (triplet changes in %) |
|----------------------------------|-----|--------------------|--------------------------------|--------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------|
| Lymphoblasts with low mutation penetrance (36–41 CAG) | 6   | 3/3                | 40.167 ± 0.983 (39–41)         | 57.250 ± 5.62 (50–63)          | 0.167 ± 0.408 (0–1)                        | 6.333 ± 1.966 (5–10)                   | 1/0                                        |
|                                  |     |                    |                                |                                |                                             |                                        | (1/6 or 17%)                             |
| Lymphoblasts with usually expanded mutation penetrance (42–59 CAG) | 43  | 22/21              | 45.628 ± 3.471 (42–54)         | 40.643 ± 10.094 (21–57)        | 0.628 ± 0.874 (0–3)                       | 7.442 ± 2.797 (3–14)                    | 6/11                                       |
|                                  |     |                    |                                |                                |                                             |                                        | (17/43 or 39%)                           |
| Lymphoblasts with high mutation penetrance (60–120 CAG) | 9   | 6/3                | 80 ± 21.042 (64–120)          | 12.750 ± 8.396 (3–25)          | 3.429 ± 1.512 (2 ≥ 5)                      | 15.429 ± 11.238 (7–40)                  | 6/3                                        |
|                                  |     |                    |                                |                                |                                             |                                        | (9/9 or 100%)                            |
| Total                            | 58  | 31/27              | 50.397 ± 15.416 (39–120)      | 37.741 ± 14.819 (3–63)         | 0.929 ± 1.333 (0–5)                       | 8.321 ± 5.250 (3–40)                    | 13/14                                     |
|                                  |     |                    |                                |                                |                                             |                                        | (27/58 or 46%)                           |

Greater CAG repeat expansions are associated with a larger number of CAG repeat changes (i.e. expansion/contraction events) in passaged lymphoblasts. DNA from passaged lymphoblasts with highest expansions of 60 CAG repeats or more causing juvenile Huntington’s disease shows a greater maximum number of peaks (p > 0.001; c vs a and b) indicating the largest triplet mosaicism and a larger number of expansion events (d) than other cell lines.
For allele length analyses, genomic DNA was purified from blood lymphocytes, and lymphoblastoid cell lines containing about 1–3 × 10^6 cells, using standard procedures (see Additional file 1 and [17]). To elucidate potential factors acting either in cis or in trans with HD mutations, we also analysed CCG repeat size, deletion of the glutamic acid residue (ΔG) at nucleotide position 2642 of the HD gene, and the CAGΔACAG mutation in the 12 base pair region between CAG and CCG repeats, on both normal and mutated genes using previously described techniques [17]. All data concerning subjects’ demographic features, cell-line mutation length and repeat number variation are included in Table 1.

**Analysis of somatic CAG repeat changes and mosaicism degree in passaged lymphoblasts**

The GeneScan traces of the PCR amplification products from patients’ passaged lymphoblastoid cell lines (see foregoing Methods) [17], appeared as a normal distribution composed of peaks differing in size by 3 bp and corresponding to a single CAG triplet change [8,19,20]. The size of the CAG repeat indicated by the highest peak corresponded to the most intense band obtained by hot PCR and was recorded as the size of the repeat in a given patient (see Additional file 2, Figure 1A). To determine the reproducibility of the CAG repeat size and its variation over time, we compared data yielded by hot and cold PCR techniques and sized samples on more than one gel. Somatic CAG repeat variation was defined by calculating the number of repeats either increased (e.g. expanded) or decreased (e.g. contracted) from the modal CAG repeat number of the expansion mutation in a given subject (see Additional file 2). Because some cell lines expanded or contracted during passages, the magnitude of the somatic CAG repeat variation in a given cell line was defined as the sum of both phenomena (expansions and contractions) occurring during the 6-month culture (see Additional file 3, Table 1). The repeat changes obtained in each cell line ranged between 0 in magnitude (no evidence of repeat changes over time, defined as ΔCAG = 0) and > 1 (ΔCAG >1), according to the number of expanded or contracted repeats or both, during 6-month culture, (see Additional files 1, 2, 3 and Table 1). The level of triplet mosaicism was expressed by the largest number of peaks calculated during the 6-month culture [8,19,20] (see Additional file 2). PCR products of normal alleles showed a single band/peak, always unchanged over-time, whereas expanded alleles consisted of multiple ladder bands/peaks, indicating somatic mosaicism. The size and range of expanded alleles varied among patients [8,19] and, sometimes, among the different cultured cell passages (see Additional file 2). To avoid artefacts potentially causing false bands or peaks due to the PCR procedure, we re-assessed the CAG size and its variation after serial dilution of DNA samples obtained from each cell line.

**Cell-line drug treatment**

In an attempt to reduce the mutation size and stability, we tested drugs influencing some of the suggested mechanisms potentially related to triplet instability [21]. For drug treatment experiments, two "stable" and two particularly "unstable" and prone-to-expand cell lines (of 74 and 85 CAG repeats) were selected. We treated cell lines with the following drugs: ethylmethanesulphonate (EMS), a GC/AT modifier thought to prevent CAG expansion in lymphoblasts derived from patients with myotonic dystrophy type 1 [22]; ethidium bromide (EB), a DNA intercalating drug reducing the rate of repeat expansion by inhibiting enzymes that bind to DNA [23]; and mitomycin C (Mit-C), an interstrand crosslinker [22]. Each progenitor culture was split into multiple aliquots: four flasks for drug treatment (one each for EMS, EB and Mit-C) and one flask for control. Each treatment was performed in duplicate. All cultures were serially passaged as previously described and maintained in parallel throughout the experiments (for further cell line culture and drug treatment methodology see Additional file 1).

**Statistical analysis**

For statistical analysis we used nonparametric tests: Mann-Whitney U test, to compare differences between cell lines with different ΔCAG (small triplet changes with ΔCAG ≤ 3 vs large triplet changes ΔCAG ≥ 5), and Kruskal-Wallis test to compare differences across more than two groups. A simple regression model was used to test the linear dependence of the maximum number of peaks (CAG mutation mosaicism) on expanded CAG repeats. Data are presented as means ± SE. Statistical analysis was performed with Stat View V (tests considered significant at p ≤ 0.05).

**Results**

**Expanded CAG repeat size-dependent changes**

Triplet variation varied over culture time in a CAG length-dependent manner (Table 1). Most passaged cell lines showed no or minimal (1 to 3 repeats) over-time triplet variation (51/58 cell lines or 88%; Table 1), including small contraction or expansion events. The repeat changes obtained in each cell line varied between 0 in magnitude (ΔCAG = 0, n = 31) and > 1 [ΔCAG > 1, n = 27; Group 1 (n = 11), 2 (n = 8), 3 (n = 3), or ≥ 5 (n = 5)], according to the number of expanded or contracted repeats or both, during 6-month culture (see Additional files 1, 2, 3 and Table 1). Cultured cell lines showing over-time triplet variation (and ΔCAG greater than 5) had, on average, a larger CAG repeat number than cell lines with no or little somatic variation (p < 0.0001, Figure 1A). The magnitude of ΔCAG significantly correlated with the size of the expanded CAG repeat: the more expanded the repeat number was, the higher were the ΔCAG values (p values ranging from 0.0041 to < 0.0001, Figure 1B). All cell lines,
regardless of their ΔCAG values, exhibited some degree of triplet mosaicism (i.e., repeats varied in size). The degree of mosaicism invariably increased significantly in cell lines carrying large expansions and ΔCAG ≥ 5 (p < 0.0001, Figure 1C). The maximum number of peaks (e.g. the level of triplet mosaicism indicating a mutation rate degree in a certain tissue) significantly correlated with ΔCAG magnitude (Figure 1D).

No significant association of investigated in cis and in trans factors influenced the repeat variation in our cohort of cell lines (see Additional file 1). Nor did we ever observe the CAAΔCAG mutation in the 12 base-pair region between CAG and CCG repeats, on either normal or mutated genes, regardless of ΔCAG values.

Figure 1

Instable cell lines with (ΔCAG ≥ 5) and stable cell lines with no or small (ΔCAG ≤ 3) CAG repeat variation in dependence on expanded CAG repeat number and mosaicism. A, Expansion CAG mutations are significantly larger in instable cell lines with ΔCAG ≥ 5 (n = 55; 89.4 ± 11.1 CAG) than in those with ΔCAG ≤ 3 (n = 55; 46.6 ± 0.10 CAG). B, Relationship between ΔCAG magnitude and expanded CAG repeat number. Groups 0, 1, 2, 3 and 5 represent cell lines with a ΔCAG value of 0, 1, 2, 3, and ≥ 5 repeats, respectively. The higher ΔCAG magnitude, the more significant is the statistical difference with Group 0-cell lines. Groups 2, 3 and 5 all showed a significant difference vs Group 0 (p-values = 0.0009, 0.0041 and < 0.0001, respectively). C, The mosaicism level, calculated by counting the maximum number of peaks, is significantly lower for stable cell lines with no or small repeat variation (n = 55, 7.4 ± 2.8 peaks and ΔCAG ≤ 3), than for those with large CAG changes (n = 5, 29.9 ± 13.7 and ΔCAG ≥ 5). D, The mosaicism level in dependence on ΔCAG: Samples with more than 80 CAG and about 40 peaks excluded as outliers to avoid a possible bias. Cell lines with large ΔCAG variations ≥ 5 CAG repeats showed an increased number of peaks and mosaicism vs each of the other groups with lower CAG variation (p-values = 0.0003, 0.0007, 0.0086 vs cell lines with ΔCAG = 0, 1 and 2 repeats, respectively). Diamonds in panels B, C and D represent outliers. Standard deviation is reported at the top of each bar.
Drug-induced CAG contraction

In experiments designed to explore whether drug treatment suppressed somatic repeat expansion [21,24], using lymphoblastoid cell lines derived from HD patients as a model, we treated two expansion-prone cell lines with EB, EMS and Mit-C, chemicals or drugs thought capable of reducing triplet expansion [22,25] (Figure 2). All the chemicals we used, EB, EMS, and Mit-C, considerably reduced CAG repeat numbers, especially in cells treated for 6 months. The drug-induced contraction apparently eliminated the bi-modal intra-allele CAG distribution in both cell lines, suggesting that triplet expansion is preventable. The same drugs failed to influence the size of the unexpanded alleles in both cell lines (see Additional files 4 and 5).

Discussion

The relatively small magnitude of triplet changes and length gains we observed in most cell lines (88% of total) confirms that cell-division related events contribute minimally to HD instability and is in agreement with the recent findings concerning CAG repeat changes mainly occurring in terminally differentiating nondividing neurons [13,14,26]. The only exception in our model were the very large expansion mutations showing increased over-time gains of CAG variations in dividing cells (see Additional file 2, Figures 1 and 2, Table 1). Lymphoblasts with highly expanded mutations are particularly prone to oxidative stress [27,28] and decreased mitochondrial ATP production [29]. More recent research has proposed a model taking into account a relationship between oxidative lesions accumulating in brain and progressive somatic gains in expanded repeats resulting from errors in repairing [26]. Hence besides mechanisms determining DNA instability as reported in differentiating neurones [13,14,26], CAG mutability might have arisen also from an age related oxidative-stress in highly expanded lymphoblasts ample evidence shows that JHD patients show extended brain damage associated with a particularly severe phenotype [4] and large mutations cause JHD, we conjecture that the cell division occurring in glial cells with large mutations may contribute to an excess of expanded repeat gains, thus contributing to more widespread brain disease, as happens in DRPLA [11,12]. This observation is in line with the hypothesis that in certain cases of HD, mutation length gains may continue to accumulate during life, as the disease progresses [30].

Consistent with a previous report [17], we found no influence on instability of the analysed factors potentially acting in-cis to the mutation (see Additional file 1), including the CAAA\CAG mutation in the 12 bp region between the CAG and CCG repeats, described by Goldberg et al. [7]. This apparent discrepancy may depend on the fact that Goldberg et al. studied a population of variable ethnic origin whereas ours was an ethnically homogeneous population [17]. Because all our cell lines showed the CAA codon on both alleles in the 12 bp region between the CAG and CCG repeats, regardless of the CAG repeat variation, we therefore rule out even the potential effect of such a factor potentially acting in trans with the CAG repeat instability in our population. The role of the normal allele size to test the hypothesis of whether the CAG repeat polymorphism in the non-HD range is a potential physiological modifier of mutation instability [29,31-33] remains to be investigated.

To reduce in vitro the mutation length of particularly large and unstable expansions and to approach a potential therapeutic strategy, we treated two cell lines with drugs thought capable of influencing mechanisms of instability [21,22,25]. When we used drugs interfering with diverse mechanisms to treat two cell lines carrying large mutations and particularly prone-to-expand, the expanded (but not the normal allele) repeat number contracted, and the bi-modal intra-allele CAG distribution progressively disappeared (Figure 2). Hence, we presume that many different mechanisms act in concert to influence CAG repeat instability. Given that somatic repeat expansion affects the HD phenotype, this finding provides useful information insofar as contracting the longest repeat number is among the putative pharmacological strategies for use in patients with HD, particularly when high expansion mutations cause early age at onset [22,25]. Intriguing questions left open for future research include the mechanisms underlying triplet repeat expansion (e.g. replication, recombination and repair processes), and their drug-induced contraction.

The main limitation of our model is probably cell proliferation induced by an infecting virus. Indeed, as recently demonstrated in HD patients, mutation length gains of CAG repeats may even occur in somatic cells or neurons well after these cells are terminally differentiated and mitotic replication has ceased. The fact that our proliferating cell model mostly disclosed small contraction/ expansion changes in few triplets nevertheless theoretically offers further strength and support to evidence that repeat length gains may occur independently of replication, as demonstrated in the striatal neuronal population [13,14,26]. An additional limitation of our work may depend on the limited (two) repetitions of the experiments. This was due to the relatively large number of cell lines cultured for long times (at least six months) with a relevant number of PCR assays required and performed each week (see Methods and Additional file 1). Therefore, the inter-experimental reproducibility is unknown as statistical significance could not be determined from the limited (two) repetitions of the experiments. Despite the potential limitations of this and other studies [15,16,27-
Figure 2 (see legend on next page)
29,34], i.e. the biological influence of the infecting virus on immortalised cells and the inter-experimental reproducibility, our study may offer an in vitro approach to human cells in the attempt to provide a new experimental model system for mechanistic studies of triplet expansion (mitotic vs repair synthesis or other mechanisms so far reported) and clinical treatments for HD.

Conclusion
Our study offers further relevance to the hypothesis that the repeat mutability depends quantitatively on CAG triplet expansion size. The longest triplet expansions show wide somatic variations and may offer a mechanistic model to study triplet drug-controlled instability. Replication does not affect somatic variability in most of the cell lines whose CAG expansion size ranges in the usual mutation penetrance confirming that cell-division related events contribute minimally to HD instability, in agreement with the findings concerning CAG repeat changes mainly occurring in terminally differentiating nondividing neurons. Instead, large repeat expansions causing JHD tend to expand during replication supporting the hypothesis that mechanisms affecting CAG mosaicism and mutability may differ in dependence on the mutation length, in certain tissues, and as the disease progresses. In our experiments certain drugs controlled triplet expansion in prone-to-expand HD cell lines carrying large CAG mutations. Finally, we found no influence on instability of the analysed factors potentially acting either in cis or in trans with the mutation, including the CAAΔCAG mutation in the 12 bp region between the CAG and CCG repeats.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
GR and FS Study concept and design. FS Drafting of the manuscript. MC, TM Acquisition of molecular genetic data. VM and GML Drug-treatment of cell lines. VM Lymphoblastoid cell line bank and virus infection. MC Art work and manuscript editing. MC, VM, GML, GR, FS Analysis and interpretation of data and statistical analysis. MC, VM, TM, GML, GR, LF, FS Critical revision of the manuscript for important intellectual content. LF, MC, TM Administrative, technical and material support. LF and FS Study supervision.

Additional material

Additional file 1
Methods, Individual cell lines from each subject, Polymorphisms analysis and statistical analysis.
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2350-10-11-S1.doc]

Additional file 2
GeneScan traces of CAG repeats in HD lymphoblastoid cell line.
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2350-10-11-S2.eps]

Additional file 3
GeneScan traces of CAG repeats in HD lymphoblastoid cell line.
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2350-10-11-S3.eps]

Additional file 4
Drug treatment in lymphoblastoid cells, effect on unexpanded alleles
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2350-10-11-S4.eps]

Additional file 5
Drug treatment in lymphoblastoid cells effect on unexpanded alleles
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2350-10-11-S5.eps]

Acknowledgements
We thank the European Huntington’s Disease Network, all patients and their families (Associazione Italiana Corea di Huntington-Neuronedo), the
References

1. The Huntington’s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993, 72:971-83.

2. Rubinstein DC, Leggo J, Amos W, Barton DE, Ferguson-Smith MA: Mutational bias provides a model for the evolution of Huntington’s disease and predicts a general increase in disease spectrum. Hum Mutat 1994, 4:201-4.

3. Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zeisler J, Amano T, Peltomaki P, Almqvist E, Sillence D, Richards J, Gusella JF: Instability of the CAG repeat in brain and sperm. Nat Genet 1994, 7:36-44.

4. Telenius H, Kremer B, Goldberg YP, Theilmann J, Andrew SE, Zeisler J, Adams M, Greenberg C, Ives E, Clarke LA, Hayden MYR: Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet 1994, 6:409-14.

5. Leeflang EP, Zhang L, Tavare S, Hubert R, Srinidhi J, MacDonald ME, RH, de Young M, Wexler NS, Gusella JF, Arnheim N: Single-sperm analysis of the trinucleotide repeats in the Huntington’s disease gene. Hum Mol Genet 1995, 4:1519-26.

6. Goldberg YP, McMurray TC, Zelser J, Almqvist E, Sillence D, Richards J, Gusella JF: OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Hum Mol Genet 1995, 4:1911-8.

7. Giovannone B, Sabbadini G, Di Maio L, Calabrese O, Castaldo I, Frontali M, Novelletto A, Squitieri F: Analysis of (CAG)n size heterogeneity in somatic and sperm cell DNA from intermediate and expanded Huntington disease gene carrier. Hum Mut 1997, 10:1-7.

8. Kennedy L, Evans E, Chen CM, Cram L, Deltoff PJ, Ennis M, Shelbourne PF: Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 2003, 12:1837-46.

9. Vatanabe H, Tanaka F, Doyu M, Biku S, Yoshida M, Hashizume Y, Sobe G: Differential somatic CAG repeat instability in variable brain cell lineage in dentatorubral pallidolysian atrophy (DRPLA): a laser-captured microdissection (LCM)-based analysis. Hum Genet 2000, 107:452-7.

10. Hashida H, Goto J, Suzuki T, Jeong S, Masuda N, Ooie T, Tachibaa Y, Tsuchiya H, Kanazawa I: Single cell analysis of CAG repeat in brains of dentatorubral-pallidolysian atrophy (DRPLA). J Neurol Sci 2000, 190(1-2):87-93.

11. Gontiel R, Moftit H, Sathasivam K, Woodman B, Deltoff PJ, Faull RL, Bates GP: DNA instability in postmitotic neurons. Proc Natl Acad Sci USA 2008, 105:3467-72.

12. Shelbourne PF, Keller-McGandy C, Bi WL, Yoon SR, Dubasu L, Vecht NJ, Vonsattel JP, Wexler NS, US-Venezuela Collaborative Research Group, Arnheim N, Augood SJ: Triploid repeat mutation length gains correlate with specific regional vulnerability in Huntington disease brain. Hum Mol Genet 2007, 16:1133-42.

13. Ashizawa T, Monckton DG, Vaishnav S, Patel BJ, Voskova A, Caskey T: Instability of the expanded (CTG)n repeats in the myotonia protein kinase gene in cultured lymphoblastoid cell lines from patients with myotonic dystrophy. Genomics 1996, 36:47-53.

14. Bidichandani SI, Purandare SM, Taylor EE, Gumin G, Machikhas H, Harati Y, Gibbs RA, Ashizawa T, Patel PI: Somatic sequence variation at the Friedreich ataxia locus includes complete contraction of the expanded GAA triplet repeat, significant length variation in serially passaged lymphoblasts and enhanced mutagenesis in the flanking sequence. Hum Mol Genet 1999, 8:2425-36.

15. Cannella M, Maglione V, Martino T, Simonelli M, Ragona G, Squitieri F: New Huntington disease mutation arising from a paternal CAG allele showing somatic length variation in serially passaged lymphoblasts. Am J Hum Genet 2005, 13:127-30.

16. Anderson MA, Gusella JF: Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines. In Vitro 1984, 20:656-68.

17. Takanoh O, Onodera O, Takahashi H, Igarashi S, Yamada M, Oyake M, Ikuechi T, Koide T, Tanaka H, Iwabuchi K, Tsujii S: Somatic mosaicism of expanded CAG repeats in brains of patients with dentatorubral-pallidolysian atrophy: cellular population-dependent dynamics of mitotic instability. Am J Hum Genet 2005, 76:1212-22.

18. Mangarin L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP: Instability of highly expanded CAG repeats in mice transgenic for the Huntington’s disease mutation. Nat Genet 1997, 15:197-200.

19. Gomes-Pereira M, Monckton DG: Chemical modifiers of unstable expanded simple sequence repeats: what goes up, comes down. Mutat Res 2006, 598:15-34.

20. Hashim VH, Pylos MJ, Klysis EK, Tsujii K, Khajavi M, Ashizawa T, Sinder RR: Chemotherapeutic deletion of CAG repeats in lymphoblasts from DM1 patients. Nucleic Acids Res 2004, 32:6334-46.

21. Thielmann HW, Popanda O, Gersbach H, Gilbert F: Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 1998, 19:2341-51.

22. Wheeler VC, Lebel A, Yrbancavan V, Teed A, Teilele, MacDonald ME: Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet 2003, 12:273-81.

23. Gomes-Pereira M, Monckton DG: Chemically induced increases and decreases in the rate of expansion of a CAG-CTG triplet repeat. Nucleic Acids Res 2004, 32:2865-72.

24. Kovtun IV, Liu Y, Bjorast M, Klungland A, Wilson SH, McMurray CT: OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 2007, 447:447-52.

25. Saw A, Wiegang GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenanlye JT, Snyder SH, Ross CA: Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1997, 3:194-8.

26. Panov AV, Gutekunst CA, Leavitt BR, Burke JR, Strittmatter WJ, Greenanlye JT: Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamyl. (Nat Neurosci 2002, 5:731-6.

27. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lessot M, MacDonald ME: HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005, 14:2871-80.

28. Kaplan S, Itzkovitz S, Shapiro E: A universal mechanism ties genotype to phenotype in trinucleotide diseases. PLoS Comput Biol 2007, 3:e235.

29. Djousse L, Knownton B, Hayden M, Almqvist EW, Brinkman R, Ross C, Margolis R, Roseblatt A, Durr A, Dade C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, Mcusker E, Gomez-Tortosa E, Mayori D, Jones R, Zankal A, Nance M, Abramson R, Suchowarsky O, Paulsen J, Harrison M, Yang Q, Cupples LA, Gusella JF, MacDonald ME, Myers RH: Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Hum Genet 2003, 71A(3):279-97.

30. Weber JL, Wong C: Mutation of human short tandem repeats. Hum Mol Genet 1993, 2:1123-8.

31. Amos W, Sawyer SJ, Feakes RW, Rubinsztein DC: Microsatellites show mutational bias and heterozygote instability. Nat Genet 1996, 13:390-1.

32. Manley A, Pugh J, Messer A: Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington’s Disease transgenic mice. Brain Res 1999, 815:74-9.

BMC Medical Genetics 2009, 10:11
http://www.biomedcentral.com/1471-2350/10/11

Page 8 of 9 (page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/10/11/prepub